Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Terbutaline

(Brethine)

 

GCEMS Protocol:

 

  • Reative Airway Disease

 

Indications:

 

  • Bronchial asthma
  • Reversible bronchospasm associated with chronic obstructive pulmonary disease

 

Contraindications:

 

  • Patients with known hypersensitivity to the medication
  • A-Fib RVR

 

Side Effects:

 

  • Tachyarrhythmias

 

Adult:

 

  • 0.25 mg SQ may be repeated once after 20 minutes

 

Peds:

 

  • 0.01 mg/kg, not to exceed 0.25 mg may repeat once after 20 minutes